ArticleBritish journal of cancer2024

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.

Akihiro Yoshimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.